Relapsed data are uncompetitive, but the front-line PACC-mutant space offers hope.
ApexOnco Front Page
Recent articles
Cross-licensing pact brings in SKB105, and hands off China rights to CR-001 before first-in-human studies.
But this adds another complexity, and has camizestrant really scored a first-line win?
The company is starting a phase 3 trial of sacituzumab tirumotecan in first-line TNBC.
The Met x Met ADC REGN5093-M114 has been discontinued, but a Met x Met bispecific antibody remains.
A key pivotal study of bemarituzumab will read out shortly.
Recent phase 1 entrants include a ROR1 ADC and a mystery Kelun project.
A triplet did worse than control in first-line kidney cancer.
